All lobbying filings

STEALTH BIOTHERAPEUTICS INC.

Lobbying for STEALTH BIOTHERAPEUTICS INC. · Developing therapies to treat mitochondrial dysfunction.

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · Massachusetts · House · Senate · $50,000.00 expenses · posted Apr 21, 2025

Official filing document

Bills named in this filing 10

HR 7384
Creating Hope Reauthorization Act of 2024
S 4583
Creating Hope Reauthorization Act of 2024
HR 1509
Accelerating Kids’ Access to Care Act of 2025
S 752
Accelerating Kids’ Access to Care Act
HR 1262
Mikaela Naylon Give Kids a Chance Act
S 932
Give Kids a Chance Act of 2025
HR 1092
BENEFIT Act of 2023
S 526
Pharmacy Benefit Manager Transparency Act of 2025
HR 1532
Scientific EXPERT Act of 2025
S 822
Scientific EXPERT Act of 2025

Lobbying activity 1

Health Issues

H.R. 7384/S. 4583, the Creating Hope Reauthorization Act of 2024 (118th Congress) H.R. 1509/S. 752 the Accelerating Kids Access to Care Act H.R. 1262/S. 932 - Give Kids a Chance Act of 2025 General discussions about ultra-rare disease drug development General discussions about regulatory reform, including scientific-focused drug development meetings H.R. 1092/S. 526, the BENEFIT Act (118th Congress) General discussions about mitochondrial diseases H.R. 1532/S. 822, the Scientific EXPERT Act of 2025 General discussions about ultra-rare diseases FDA Rare Disease Innovation Hub

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.